Results overview: Found 4 records in 0.02 seconds.
Articles, 4 records found
Articles 4 records found  
1.
9 p, 267.2 KB A Topical Treatment Optimization Programme (TTOP) improves clinical outcome for calcipotriol/betamethasone gel in psoriasis : results of a 64-week multinational randomized phase IV study in 1790 patients (PSO-TOP) / Reich, Kristian (SCIderm GmbH) ; Zschocke, I. (SCIderm GmbH) ; Bachelez, Hervé (AP-HP Hôpital Saint-Louis) ; de Jong, E.M.G.J. (Radboud University Medical Centre and Radboud University) ; Gisondi, Paolo (University of Verona) ; Puig Sanz, Lluís (Institut d'Investigació Biomèdica Sant Pau) ; Warren, R. B. (Manchester Academic Health Science Centre) ; Ortland, C. (Das Forschungsdock Service for Clinical Development) ; Mrowietz, Ulrich (University Medical Center Schleswig-Holstein) ; Universitat Autònoma de Barcelona
Around two-thirds of patients with psoriasis do not adhere to topical treatment. The Topical Treatment Optimization Programme (TTOP), a five-element tool, includes guidance for the conversation between dermatologists/nurses and patients, patient information material, telephone/e-mail helpdesks and treatment reminders. [...]
2017 - 10.1111/bjd.15466
British journal of dermatology, Vol. 177 Núm. 1 (july 2017) , p. 197-205  
2.
6 p, 377.9 KB Clinical and genetic differences between pustular psoriasis subtypes / Twelves, Sophie (King's College London) ; Mostafa, Alshimaa (Beni Suef University) ; Dand, Nick (King's College London) ; Burri, Elias (University Hospital Zurich (Suïssa)) ; Farkas, K. (University of Szeged) ; Wilson, Rosemary (King's College London) ; Cooper, Hywel L. (Portsmouth Hospitals Trust) ; Irvine, Alan D. (Trinity College Dublin) ; Oon, Hazel H. (National Skin Centre) ; Kingo, Külli (Tartu University Hospital (Tartu, Estònia)) ; Köks, Sulev (University of Tartu) ; Mrowietz, Ulrich (University Medical Center Schleswig-Holstein) ; Puig Sanz, Lluís (Institut d'Investigació Biomèdica Sant Pau) ; Reynolds, Nick (Newcastle Hospitals NHS Foundation Trust) ; Tan, Euegene Sern-Ting (National Skin Centre) ; Tanew, Adrian (Medical University of Vienna) ; Torz, Kaspar (Campus Kiel) ; Trattner, Hannes (Medical University of Vienna) ; Valentine, Mark (University of Washington School of Medicine) ; Wahie, Shyamal (University Hospital of North Durham and Darlington Memorial Hospital) ; Warren, Richard B. (University of Manchester and the Academic Health Science Centre) ; Wright, Andrew (St University of Bradford) ; Bata-Csörgő, Zsuzsa (University of Szeged) ; Szell, Marta (University of Szeged) ; Griffiths, Christopher E.M. (University of Manchester and the Academic Health Science Centre) ; Burden, A.David (University of Glasgow) ; Choon, Siew-Eng (Monash University Malaysia) ; Smith, Catherine H. (King's College London) ; Barker, Jonathan N. (King's College London) ; Navarini, Alexander A. (University Hospital Zurich (Suïssa)) ; Capon, Francesca (King's College London) ; Universitat Autònoma de Barcelona
The term pustular psoriasis indicates a group of severe skin disorders characterized by eruptions of neutrophil-filled pustules. The disease, which often manifests with concurrent psoriasis vulgaris, can have an acute systemic (generalized pustular psoriasis [GPP]) or chronic localized (palmoplantar pustulosis [PPP] and acrodermatitis continua of Hallopeau [ACH]) presentation. [...]
2019 - 10.1016/j.jaci.2018.06.038
The Journal of Allergy and Clinical Immunology, Vol. 143 Núm. 3 (march 2019) , p. 1021-1026  
3.
9 p, 1013.2 KB Long-term efficacy and safety of brodalumab in moderate-to-severe plaque psoriasis : a post hoc pooled analysis of AMAGINE-2 and -3 / Reich, Kristian (University Medical Center Hamburg-Eppendorf) ; Iversen, L. (Aarhus University Hospital (Aarhus, Dinamarca)) ; Puig Sanz, Lluís (Institut d'Investigació Biomèdica Sant Pau) ; Lambert, Jo (Ghent University) ; Mrowietz, Ulrich (University Medical Center Schleswig-Holstein) ; Kaplan Saday, K. (LEO Pharma A/S) ; Warren, R. B. (University of Manchester) ; Universitat Autònoma de Barcelona
Brodalumab is a monoclonal antibody that blocks multiple interleukin (IL)-17 family cytokines by binding to the shared A subunit of the IL-17 receptor. In Phase 3 trials, brodalumab provided high levels of skin clearance through 52 weeks in patients with moderate-to-severe psoriasis and was generally well tolerated. [...]
2022 - 10.1111/jdv.18068
Journal of the European Academy of Dermatology and Venereology, Vol. 36 Núm. 8 (august 2022) , p. 1275-1283  
4.
12 p, 1.1 MB The role of the interleukin-23/Th17 pathway in cardiometabolic comorbidity associated with psoriasis / Egeberg, A. (Gentofte Hospital) ; Gisondi, Paolo (University of Verona) ; Carrascosa, José Manuel (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Warren, R. B. (Manchester NIHR Biomedical Research Centre) ; Mrowietz, Ulrich (University Medical Center Schleswig-Holstein) ; Universitat Autònoma de Barcelona
Alterations in the innate and adaptive immunity underpin psoriasis pathophysiology, with the Th17 cells subset now recognized as the fundamental cells in the key controlling pathway involved in its pathogenesis. [...]
2020 - 10.1111/jdv.16273
Journal of the European Academy of Dermatology and Venereology, Vol. 34 (march 2020) , p. 1695-1706  

See also: similar author names
5 Mrowietz, Ulrich
Interested in being notified about new results for this query?
Set up a personal email alert or subscribe to the RSS feed.